<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Tuhura Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/tuhura-biosciences-inc</link>
<description>Latest news and press releases for Tuhura Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/tuhura-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835804478dffbe2df0fb5e8.webp</url>
<title>Tuhura Biosciences Inc</title>
<link>https://6ix.com/company/tuhura-biosciences-inc</link>
</image>
<item>
<title>TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-announces-dollar50-million-credit-facility-and-royalty-transaction-extending-anticipated-cash-runway-into-2028-9</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-announces-dollar50-million-credit-facility-and-royalty-transaction-extending-anticipated-cash-runway-into-2028-9</guid>
<pubDate>Wed, 22 Apr 2026 04:00:00 GMT</pubDate>
<description>Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement</description>
</item>
<item>
<title>TuHURA Biosciences Appoints Amanda Garofalo, MSHS, as Senior Vice President of Clinical Operations</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-appoints-amanda-garofalo-mshs-as-senior-vice-president-of-clinical-operations</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-appoints-amanda-garofalo-mshs-as-senior-vice-president-of-clinical-operations</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>Mrs. Garofalo brings over 20 years of experience in Phase I-IV drug and biologic developmentTAMPA, Fla., April 7, 2026 /PRNewswire/ -- TuHURA Biosciences,</description>
</item>
<item>
<title>TuHURA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>TAMPA, Fla., April 1, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing</description>
</item>
<item>
<title>Craig Tendler, M.D., JNJ's Former Global Head of Oncology Clinical Development, to Lead TuHURA Bioscience's VISTA Program in AML and other Blood Related Cancers</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/craig-tendler-md-jnjs-former-global-head-of-oncology-clinical-development-to-lead-tuhura-biosciences-vista-program-in-aml-and-other-blood-related-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/craig-tendler-md-jnjs-former-global-head-of-oncology-clinical-development-to-lead-tuhura-biosciences-vista-program-in-aml-and-other-blood-related-cancers</guid>
<pubDate>Mon, 23 Mar 2026 11:45:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced Dr. Craig L. Tendler will provide strategic, operational and other related services consistent with those of a Chief Medical Officer (CMO). He will also continue with his current role as member of the Board of Directors. Dr. Tendler will work with the Company to oversee clinical development strategy and</description>
</item>
<item>
<title>TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-regains-compliance-with-nasdaq-minimum-bid-price-requirement</guid>
<pubDate>Fri, 27 Feb 2026 12:30:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that on February 26, 2026, it received written notice from the Nasdaq Stock Market LLC (Nasdaq) confirming that the Company has regained compliance with Nasdaq's $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550 (a)(2) (the "Listing Rule"). Nasdaq confirmed that for the last 11 consecut</description>
</item>
<item>
<title>TuHURA Biosciences Announces Participation in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-announces-participation-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-announces-participation-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>TAMPA, Fla., Feb. 24, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing</description>
</item>
<item>
<title>TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-files-investigational-new-drug-application-for-tbs-2025-in-the-treatment-of-blood-related-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-files-investigational-new-drug-application-for-tbs-2025-in-the-treatment-of-blood-related-cancers</guid>
<pubDate>Tue, 17 Feb 2026 12:45:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration's (FDA) Division of Hematologic Malignancies 1 (DHM1) for the study of TBS-2025, a novel VISTA inhibiting antibody, for the treatment of mutNPM1 relapsed/refractory (r/r) Acute Myeloid Leukemia (AM</description>
</item>
<item>
<title>TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-present-oppenheimer-36th-124500722</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-present-oppenheimer-36th-124500722</guid>
<pubDate>Thu, 12 Feb 2026 12:45:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference.</description>
</item>
<item>
<title>TuHURA Biosciences received FDA Orphan Drug Designation for IFx-2.0 for the Treatment of Stage IIB to Stage IV Cutaneous Melanoma</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-received-fda-orphan-124500971</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-received-fda-orphan-124500971</guid>
<pubDate>Mon, 02 Feb 2026 12:45:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S Food and Drug Administration's (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma.</description>
</item>
<item>
<title>TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-announces-release-kintaras-125000886</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-announces-release-kintaras-125000886</guid>
<pubDate>Mon, 15 Dec 2025 12:50:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that Kintara's REM-001 clinical trial of ten metastatic cutaneous breast cancer patients met its primary endpoint demonstrating safety with signs of clinical efficacy following eight weeks of follow-up for such patients.</description>
</item>
<item>
<title>TuHURA Biosciences Provides Corporate Update Following Recent Financing</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-provides-corporate-following-123000004</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-provides-corporate-following-123000004</guid>
<pubDate>Thu, 11 Dec 2025 12:30:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided updates across the company's portfolio of assets, including a summary from its mini symposium held on December 5, 2025 focused on targeting VISTA in AML, the scientific rational and clinical applications in NPM1 mutated r/r AML in combination with a menin inhibitor. The company's recently announced financing transaction,</description>
</item>
<item>
<title>TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-announces-15-144900759</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-announces-15-144900759</guid>
<pubDate>Tue, 09 Dec 2025 14:49:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 9,462,423 shares of its common stock, Series A warrants to purchase up to an aggregate of 9,462,423 shares of its common stock and Series B warrants to purchase up to an aggregate of 9,462,423 shares of its common stock,</description>
</item>
<item>
<title>TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-presents-data-demonstrating-125000955</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-presents-data-demonstrating-125000955</guid>
<pubDate>Mon, 08 Dec 2025 12:50:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its research on the potential role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of MDSCs was presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition that took place on Sunday, December 7 in Orlando, FL. The Company pres</description>
</item>
<item>
<title>TuHURA Biosciences, Inc. Reports Third Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-reports-third-120000472</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-reports-third-120000472</guid>
<pubDate>Fri, 14 Nov 2025 12:00:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's third quarter ended September 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>TuHURA Biosciences Discovery Research on Targeting the Delta Opioid Receptor (DOR) to Reprogram Myeloid-Derived Suppressor Cells (MDSCs) Selected for Oral Presentation at the 67th ASH Annual Meeting and Exposition</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-discovery-research-targeting-140100541</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-discovery-research-targeting-140100541</guid>
<pubDate>Mon, 03 Nov 2025 14:01:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that its research on the potential role of the Delta Opioid Receptor in controlling the immunosuppressive capabilities of MDSCs was accepted for an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Orlando, FL from December 6-9, 2025. TuHURA will present th</description>
</item>
<item>
<title>TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-present-27th-120000192</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-present-27th-120000192</guid>
<pubDate>Wed, 20 Aug 2025 12:00:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City.</description>
</item>
<item>
<title>TuHURA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-reports-second-201500352</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-reports-second-201500352</guid>
<pubDate>Thu, 14 Aug 2025 20:15:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2025, and provided a corporate update.</description>
</item>
<item>
<title>TuHURA Biosciences, Inc. Announces Inclusion in the Russell 3000® and Russell 2000® Indexes</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-announces-inclusion-125000488</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-inc-announces-inclusion-125000488</guid>
<pubDate>Tue, 01 Jul 2025 12:50:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced that the Company has been added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, as a part of the 2025 Russell indexes annual reconstitution. The Company's addition to the Russell 3000® Index and the Russell 2000® Index was effective as of market close, Friday, June 27th,</description>
</item>
<item>
<title>TuHURA Biosciences Completes Acquisition of Kineta</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-completes-acquisition-kineta-125000602</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-completes-acquisition-kineta-125000602</guid>
<pubDate>Mon, 30 Jun 2025 12:50:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the successful completion of the acquisition of Kineta, Inc. (OTCPK:KANT) ("Kineta"), the maker of the novel VISTA inhibiting mAb formerly known as KVA1213, now renamed as TBS-2025.</description>
</item>
<item>
<title>TuHURA Biosciences Initiates Its Phase 3 Accelerated Approval Trial of IFx-2.0 as an Adjunctive Therapy to Keytruda® (pembrolizumab) in First Line Treatment for Advanced or Metastatic Merkel Cell Carcinoma</title>
<link>https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-initiates-phase-3-120000438</link>
<guid isPermaLink="true">https://6ix.com/company/tuhura-biosciences-inc/news/tuhura-biosciences-initiates-phase-3-120000438</guid>
<pubDate>Tue, 24 Jun 2025 12:00:00 GMT</pubDate>
<description>TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today announced the initiation of its Phase 3 accelerated approval trial of IFx-2.0, TuHURA's lead innate immune agonist, in patients with advanced or metastatic Merkel cell carcinoma (MCC).</description>
</item>
</channel>
</rss>